MediPharm Labs Alerts Shareholders to Allegations Made Against Regan McGee in Multiple Litigation Filings

Core Viewpoint - MediPharm Labs Corp. is addressing concerns regarding Regan McGee, a dissident shareholder and CEO of Apollo Technology Capital Corporation, who is seeking to elect himself and five other directors to the MediPharm board at the upcoming shareholder meeting [1][2]. Group 1: Allegations Against Regan McGee - Allegations have been made against Mr. McGee regarding his business conduct, including claims of misusing company resources and setting his own compensation through a conflicted process [3][6]. - Former colleagues of Mr. McGee have accused him of misrepresenting the nature of Nobul Technologies Inc.'s business, claiming it was a technology innovator when it primarily operated as a traditional real estate brokerage [7][8]. - There are serious allegations that Mr. McGee and his associates misled investors about Nobul's financial health and used funds for personal enrichment rather than business expansion [12][14]. Group 2: Legal Proceedings - Multiple litigation cases involving Nobul Technologies Inc. and Mr. McGee have been cited, including claims of fraudulent misrepresentation and breach of fiduciary duty [26][30]. - The allegations in these cases include claims that Mr. McGee used Nobul as a façade to deceive investors, leading to significant financial losses for those who invested based on misleading information [13][14]. - The legal actions also highlight governance issues, with former directors expressing concerns about Mr. McGee's control over the company and the lack of transparency in operations [10][11]. Group 3: MediPharm's Position - MediPharm urges shareholders to support its nominees and resolutions by voting with the GREEN proxy, emphasizing the importance of governance and the qualifications of its board members [16][17]. - The company has communicated that shareholders should disregard any outreach from the dissident group and focus on the information provided by MediPharm [18].